Pediatrix Therapeutics
- Company typePrivate
- Founded2021
- HeadquartersXuhui, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Pediatrix Therapeutics firmographics
Firmographics- Name
- Pediatrix Therapeutics
- Legal name
- 祐儿医药 Pediatrics Therapeutics
- Website
- https://pediatrixtherapeutics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Pediatrix Therapeutics industry classification
Industry- Product category
- Pediatric Allergy Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
Keywords
Where Pediatrix Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Xuhui
- HQ country
- China
- HQ region
- Asia
Markets served
Pediatrix Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Marketing or Sales, Personnel, Technology or R&D, Supply Chain
Revenue model
- Product Licensing and Commercialization: Pediatrix Therapeutics commercializes neffy in China under a licensing agreement with ARS Pharmaceuticals. The company receives regulatory milestone payments ($4 million received) and is eligible for additional sales milestones up to $80 million plus tiered royalties on net sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Pediatrix Therapeutics product offering
Product offeringCore offering
Pediatrix Therapeutics is a China-based biopharmaceutical company that holds an exclusive licensing agreement with ARS Pharmaceuticals to commercialize neffy (epinephrine nasal spray), marketed as 优敏速® in China. The company received NMPA approval in December 2025 and is responsible for bringing the product to market in China, with availability expected in spring 2026. neffy is a needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions including anaphylaxis in adults and children weighing 30 kg or more.
Product overview
Pediatrix Therapeutics is a biopharmaceutical company commercializing neffy (epinephrine nasal spray) in China. The company holds exclusive licensing rights from ARS Pharmaceuticals to commercialize neffy 2mg, marketed as 优敏速® in China. neffy is a needle-free intranasal epinephrine delivery system designed for emergency treatment of severe allergic reactions and anaphylaxis. The product represents a novel alternative to traditional injectable epinephrine, offering convenient nasal administration for patients weighing 30 kg or more.
Differentiator
Problem solved
Functional benefit
Products and services
- neffy 2mg (优敏速®) Needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions including anaphylaxis in adults and children weighing 30 kg or more. The first community-use epinephrine product approved in China.
Quantifiable outcome
- First needle-free epinephrine option for over 50-100 million allergy sufferers in China
Companies that use Pediatrix Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Pediatrix Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Pediatrix Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ARS PharmaceuticalscorePediatrix Therapeutics holds an exclusive licensing agreement with ARS Pharmaceuticals to commercialize neffy (epinephrine nasal spray) in China. The partnership includes $4 million regulatory milestone payment received upon NMPA approval, with potential additional sales milestones up to $80 million plus tiered royalties on net sales. The product is marketed as 优敏速® in China and expected to be available by spring 2026.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Pediatrix Therapeutics competitors and assessment
Company assessmentDirect peers
- ARS Pharmaceuticals: ARS Pharmaceuticals is the originator of neffy and Pediatrix Therapeutics' licensor. They share the same product and revenue model (licensing + royalties), making them the most directly comparable peer in commercial structure and economics.
- ALK-Abelló: ALK-Abelló is the exclusive licensing partner commercializing neffy in Canada under a November 2024 agreement. It operates an identical commercial model to Pediatrix (licensing partner for neffy in a specific geography) and serves as the most direct functional comparison.
- Zai Lab: Zai Lab is a China-focused biotech that licenses and commercializes Western-developed specialty therapeutics. Pediatrix shares Zai Lab's China-licensing commercialization model and target patient population (specialty/rare disease focus).
- Hutchmed (China): Hutchmed develops and commercializes specialty oncology and immunology drugs in China, often via in-licensed or co-developed assets. Comparable to Pediatrix in the China specialty pharma commercialization model.
- Amphastar Pharmaceuticals: Amphastar manufactures and markets epinephrine products (including nasal and injectable forms) in the U.S. and global markets. It is one of the few pure-play epinephrine product companies and a direct therapeutic-area comparable to Pediatrix.
Broad incumbents
- BeiGene: BeiGene is a larger, established China-rooted biopharmaceutical company commercializing innovative therapies across multiple therapeutic areas. While broader in scope than Pediatrix, it illustrates the scaled China specialty pharma model Pediatrix aspires to.
- Pfizer (EpiPen): Pfizer commercializes EpiPen, the dominant injectable epinephrine product globally. It represents the established incumbent in the allergy/anaphylaxis emergency treatment category Pediatrix is competing in.
- Teva Pharmaceutical Industries: Teva markets generic epinephrine auto-injectors as a lower-cost alternative to EpiPen, serving as a pricing benchmark and competitive threat in the same therapeutic category Pediatrix addresses.
- Bausch + Lomb (Emerade): Bausch + Lomb markets Emerade, an epinephrine auto-injector product. As another established player in the global epinephrine emergency-treatment market, it offers a relevant incumbency comparison.
Regional players
- Sino Biopharmaceutical: Sino Biopharmaceutical is one of China's largest domestic pharma companies with significant respiratory and allergy-related product portfolios. As a domestic incumbent with established distribution, it represents a key regional competitor in Pediatrix's target market.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Pediatrix Therapeutics social profiles
Digital presencePediatrix Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pediatrix Therapeutics leadership team
Management profileNumber of profiles
Pediatrix Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pediatrix Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pediatrix Therapeutics
What does Pediatrix Therapeutics do?
Pediatrix Therapeutics is a China-based biopharmaceutical company that holds an exclusive licensing agreement with ARS Pharmaceuticals to commercialize neffy (epinephrine nasal spray), marketed as 优敏速® in China. The company received NMPA approval in December 2025 and is responsible for bringing the product to market in China, with availability expected in spring 2026. neffy is a needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions including anaphylaxis in adults and children weighing 30 kg or more.
Is Pediatrix Therapeutics a public or private company?
Pediatrix Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pediatrix Therapeutics founded?
Pediatrix Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is Pediatrix Therapeutics based?
Pediatrix Therapeutics is headquartered in Xuhui, China, in the Asia region.
How does Pediatrix Therapeutics make money?
One revenue line is on record: product Licensing and Commercialization.
Who are Pediatrix Therapeutics's main competitors?
Direct peers on record are ARS Pharmaceuticals, ALK-Abelló, Zai Lab, Hutchmed (China) and Amphastar Pharmaceuticals. Broad incumbents are BeiGene, Pfizer (EpiPen), Teva Pharmaceutical Industries and Bausch + Lomb (Emerade). Sino Biopharmaceutical is listed as a regional player.
Does Pediatrix Therapeutics have an API?
No public API is recorded for Pediatrix Therapeutics.
What industry is Pediatrix Therapeutics in?
Pediatrix Therapeutics's product category is Pediatric Allergy Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 325411 and its SIC code is 2834.